1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Australia Unveils Proposals For Overhauling HTA System

 
• By Ian Schofield

Ideas proposed under the consultation include more guidance in areas such as real-world data and the assessment of genomic and tumor agnostic therapies, a single gateway for HTA filings, and more active horizon scanning.

Benefit_Cost
Australia has produced a set of options for improving HTA methods and policies • Source: Shutterstock

The Australian government has begun a consultation asking stakeholders for their views on a set of options for improving the country’s health technology assessment (HTA) policies and methods as well as funding and assessment pathways.

The options are outlined in a paper drafted by the HTA Review Reference Committee as part of the HTA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Market Access

340B Rebate Model Gets HRSA Endorsement; Pilot Program Limited To Medicare Negotiated Drugs

 
• By Cathy Kelly

Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.

Mexico Speeds Up Market Access With Regulatory Reliance Guidelines

 
• By Francesca Bruce

Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.